In cardiovascular medicine, claims of ‘mortality reduction’ are widely used to summarise the benefits of contemporary therapies. The phrase carries a powerful and intuitive meaning, suggesting that deaths have been prevented and lives have been saved. However, a closer examination of many cardiovascular outcome trials shows that this conclusion often reflects an interpretative shortcut rather than a fundamental difference in outcomes.
\nMost trials rely on time-to-event analyses that demonstrate differences in the timing of death within a limited follow-up period. These findings are frequently translated into statements of reduced mortality, even when the observed effect primarily represents a modest extension of survival rather than the prevention of death. Although statistically correct within the predefined time horizon, this framing may overstate clinical benefit and obscure the time-dependent nature of survival outcomes.
\nThis Viewpoint examines the conceptual distinction between delaying death and preventing it, and explores how this distinction is often blurred in trial reporting, abstracts, guideline summaries and clinical communication. By converting time gained into categorical claims of deaths avoided, survival benefits may acquire a clinical and moral weight that exceeds their absolute magnitude, influencing therapeutic expectations, guideline recommendations and patient decision-making.
\nThe aim is not to question the validity of survival analysis but to highlight the importance of interpretative precision once statistical results are translated into clinical language. Greater clarity in distinguishing survival extension from mortality reduction would support more transparent communication of benefit, facilitate shared decision-making and better align reported outcomes with what patients ultimately experience and value.
\nIn an era of increasingly complex cardiovascular interventions, precision in how benefits are described is a necessary component of high-quality, patient-centred care.
"}